Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nuvastatic in non-proliferative diabetic retinopathy
NCT04552600Phase 2Completed
- Sponsor
- Natureceuticals
- Start
- Sep 2019
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic retinopathy (DR) comparing Nuvastatic 1000 mg with Placebo (2 arms). Primary endpoints: Retinal Thickness at 12 months, Protein Biomarkers at 12 months and 1 more. Started Sep 2019; status: completed.
02
Drugs
Nuvastatic
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT04552600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04552600.